Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): February 10, 2014


Esperion Therapeutics, Inc.

(Exact name of registrant as specified in its charter)







(State or other jurisdiction of


(Commission File Number)


(I.R.S. Employer
Identification No.)


46701 Commerce Center Drive

Plymouth, MI



(Address of principal executive offices)


(Zip Code)


Registrant’s telephone number, including area code: (734) 862-4840


Not Applicable

Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On February 10, 2014, Esperion Therapeutics, Inc. (the “Company”) elected Mark E. McGovern, M.D., to the Board of Directors of the Company.  Dr. McGovern was elected as a Class I director and will serve until the Company’s annual meeting of stockholders in 2014 or until his successor is duly elected and qualified.


Dr. McGovern is a board-certified cardiologist with over 20 years of experience developing lipid regulating therapies, and since 2007, has served as a consultant to the pharmaceutical industry in cardiovascular and lipid regulation.  Dr. McGovern’s experience includes 11 years at Bristol-Myers Squibb (NYSE: BMY), from 1986 to 1997, in various capacities, including Executive Director, Heart Failure and Atherosclerosis Clinical Research.  Dr. McGovern subsequently spent 10 years, from 1997 to 2007, at Kos Pharmaceuticals, where he last served as executive vice president, medical affairs, and chief medical officer, prior to its acquisition by Abbott Laboratories.  Dr. McGovern earned his Bachelor’s degree summa cum laude from Princeton University and his medical degree from the University of Vermont.  Dr. McGovern is a Fellow of the American College of Cardiology and the American College of Physicians, and has published extensively on lipid management and its role in the treatment of coronary heart disease.  The Company believes that Dr. McGovern is qualified to serve as a director based on his broad experience in the industry in which it operates.


As a non-employee director, Dr. McGovern will receive cash and equity compensation paid by the Company pursuant to its non-employee director compensation program. There are no arrangements or understandings between Dr. McGovern and any other person pursuant to which Dr. McGovern was selected as a director, and there are no transactions between Dr. McGovern and the Company that would require disclosure under Item 404(a) of Regulation S-K.


*    *     *






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: February 14, 2014

Esperion Therapeutics, Inc.





/s/ Tim M. Mayleben



Tim M. Mayleben



President and Chief Executive Officer